SCHEMBL1352258

SCHEMBL1352258

CC(C)(Oc1ccc(CCNC[C@@H](O)c2ccccc2)cc1)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ADRB3 P13945 10/20 1.00
KDM4E B2RXH2 2/20 0.69
GAA P10253 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.69
TDP1 Q9NUW8 1/20 0.69
ADRB2 P07550 2/20 0.56
PPARA Q07869 2/20 0.54
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
MAPT P10636 1/20 0.53
ADRB1 P08588 1/20 0.53
PPARG P37231 1/20 0.52
ALOX15 P16050 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1352261 1.00 ADRB3 (1.00) ADRB3KDM4EGAASMN1; SMN2TDP1
SCHEMBL1351960 1.00 ADRB3 (1.00) ADRB3KDM4EGAASMN1; SMN2TDP1
SCHEMBL1352847 0.88 ADRB3 (0.78) ADRB3ADRB1
SCHEMBL1352546 0.88 ADRB3 (0.78) ADRB3ADRB1
SCHEMBL1352848 0.88 ADRB3 (0.78) ADRB3ADRB1
SCHEMBL3848024 0.85 ADRB3 (0.73) ADRB3KDM4ESMN1; SMN2PPARAMEN1
Hydrochloric Acid SCHEMBL6540535 0.82 ADRB3 (0.68) ADRB3ADRB1
Hydrochloric Acid SCHEMBL6540530 0.82 ADRB3 (0.68) ADRB3ADRB1
SCHEMBL9545805 0.81 SMN1; SMN2 (0.73) ADRB3KDM4EGAASMN1; SMN2TDP1
SCHEMBL10717538 0.81 KDM4E (0.90) ADRB3KDM4EGAASMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100075977-A1 BETA-3 RECEPTOR LIGANDS AND THEIR USE IN THERAPY UNVERSITA' DEGLI STUDI DI BARI (IT) 2010-03-25 US claimed
EP-2046722-A2 BETA-3 RECEPTOR LIGANDS AND THEIR USE IN THERAPY Universita' Degli Studi di Bari (IT) 2009-04-15 EP claimed
WO-2008015558-A2 BETA-3 RECEPTOR LIGANDS AND THEIR USE IN THERAPY UNIVERSITA' DEGLI STUDI DI BARI (IT) 2008-02-07 WO claimed
EP-2759540-A2 Beta-3 receptor ligands and their use in therapy Universita' Degli Studi di Bari (IT) 2014-07-30 EP disclosed
US-8354412-B2 Beta-3 receptor ligands and their use in therapy UNIVERSITA' DEGLI STUDI DI BARI (IT) 2013-01-15 US disclosed
US-20110288104-A1 Beta-3 receptor ligands and their use in therapy UNIVERSITA' DEGLI STUDI DI BARI (IT) 2011-11-24 US disclosed
US-8017613-B2 Beta-3 receptor ligands and their use in therapy UNIVERSITA' DEGLI STUDI DI BARI (IT) 2011-09-13 US disclosed
US-20100075977-A1 BETA-3 RECEPTOR LIGANDS AND THEIR USE IN THERAPY UNVERSITA' DEGLI STUDI DI BARI (IT) 2010-03-25 US disclosed
EP-2046722-A2 BETA-3 RECEPTOR LIGANDS AND THEIR USE IN THERAPY Universita' Degli Studi di Bari (IT) 2009-04-15 EP disclosed
WO-2008015558-A2 BETA-3 RECEPTOR LIGANDS AND THEIR USE IN THERAPY UNIVERSITA' DEGLI STUDI DI BARI (IT) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075977-A1 BETA-3 RECEPTOR LIGANDS AND THEIR USE IN THERAPY ADRB3, ADRB2, ADRB1 ADRB3 1/4885KDM4E 4659/4885GAA 3398/4885
US-20110288104-A1 Beta-3 receptor ligands and their use in therapy ADRB3, ADRB2, ADRB1 ADRB3 1/4885KDM4E 4659/4885GAA 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.